12:00 AM
 | 
Apr 07, 2003
 |  BioCentury  |  Finance

1Q Wrap-Up: Relatively unnoticed

If one could produce a first quarter Nielsen Rating on the biotech group, it would be like one of those "quality" TV shows that nobody watches. With investors riveted on the Iraq conflict, Wall Street seemed to care more about safe havens than biotech fundamentals. That's too bad, because the industry put in a solid quarter on the fundamentals: approvals out-numbered significant late-stage setbacks close to 2-1 (see "Approvals/Setbacks," A20).The approvals included the first ever biologic to treat psoriasis - Amevive...

Read the full 388 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >